A fully integrated biotech platform for extracellular vesicles.
From research and IP to manufacturing, licensing and commercialization, BioThera runs every stage of its extracellular vesicle platform in Ottawa, Canada. BioThera is closing its current round in fall 2026. Investors and strategic partners are welcome to request information.
Why EV Biomanufacturing?
The bottleneck in extracellular vesicle applications is not the science. It is reproducible manufacturing at scale, characterized to a standard a buyer can verify. That is the layer BioThera operates.
A Defining EV Technology Platform
EVs are a powerful biological delivery system: characterized, standardized, and engineered for performance. BioThera is not building a single product. We are building the source-flexible EV platform that applications across the field require, starting with cosmetic applications and extending to therapeutic research.
The Infrastructure Gap
Scalable, standardized EV manufacturing is the critical missing piece preventing the EV field from maturing. We are building that infrastructure with documented quality control on every batch and the velocity of a startup.
Regulatory-Efficient Path
Cosmetic applications provide a regulatory-efficient path to validate the platform in the real world, generating operational data and proof points that carry across every application the platform supports.
Request Information
If you would like to understand the platform, the characterization standard or the licensing model, submit a request below and we will follow up.
Detailed Materials
Technical data packages, characterization records and platform documentation are shared selectively and under NDA. Submit a request above.
Forward-Looking NoticeThis page contains forward-looking statements based on current expectations. Actual results may differ materially. Nothing on this page constitutes an offer to sell or solicitation of an offer to buy securities. Any offering will be conducted under applicable private placement exemptions.
This page is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction. Any offering of securities by BioThera Solutions Inc. will be conducted on a private placement basis pursuant to applicable exemptions, including the accredited investor exemption under National Instrument 45-106 (Canada), Rule 506 of Regulation D under the Securities Act of 1933 (United States), and equivalent private placement exemptions in other jurisdictions. Participation in any offering is restricted to accredited investors, qualified investors, or other persons eligible under applicable securities law exemptions in their respective jurisdiction. Forward-looking statements reflect current expectations and are subject to known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially. This communication does not constitute investment advice. Past performance is not indicative of future results.